<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font20 { font-size : 20; } .font22 { font-size : 22; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font28 { font-size : 28; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font28">and </span>
   <span class="font22">with </span>
   <span class="font20">patients </span>
   <span class="font16">for </span>
   <span class="font15">ICI </span>
   <span class="font15">immune </span>
   <span class="font15">that </span>
   <span class="font14">checkpoint </span>
   <span class="font14">cancer </span>
   <span class="font13">cell </span>
   <span class="font13">PD- </span>
   <span class="font13">are </span>
   <span class="font13">viral </span>
   <span class="font12">COVID- </span>
   <span class="font12">may </span>
   <span class="font12">{background </span>
   <span class="font12">not </span>
   <span class="font12">infection </span>
   <span class="font12">treatment </span>
   <span class="font12">cells </span>
   <span class="font12">chronic </span>
   <span class="font12">HIV </span>
   <span class="font12">The </span>
   <span class="font12">influenza </span>
   <span class="font12">was </span>
   <span class="font11">margin </span>
   <span class="font11">receiving </span>
   <span class="font11">risk </span>
   <span class="font11">this </span>
   <span class="font11">{border-style </span>
   <span class="font11">lymphocytes </span>
   <span class="font11">vaccination </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">from </span>
   <span class="font11">inhibitors </span>
   <span class="font11">also </span>
   <span class="font11">use </span>
   <span class="font11">advanced </span>
   <span class="font11">associated </span>
   <span class="font11">clinical </span>
   <span class="font11">disease </span>
   <span class="font11">have </span>
   <span class="font11">lung </span>
   <span class="font11">reported </span>
   <span class="font11">who </span>
   <span class="font11">HBV </span>
   <span class="font11">data </span>
   <span class="font11">efficacy </span>
   <span class="font11">has </span>
   <span class="font11">hepatitis </span>
   <span class="font11">should </span>
   <span class="font11">expression </span>
   <span class="font11">irAEs </span>
   <span class="font11">severe </span>
   <span class="font11">such </span>
   <span class="font11">therapy </span>
   <span class="font11">adverse </span>
   <span class="font11">both </span>
   <span class="font11">immunosuppressive </span>
   <span class="font11">increased </span>
   <span class="font11">syndrome </span>
   <span class="font11">were </span>
   <span class="font11">COVID-. </span>
   <span class="font11">However, </span>
   <span class="font11">activation </span>
   <span class="font11">been </span>
   <span class="font11">exhaustion </span>
   <span class="font11">infection. </span>
   <span class="font11">multifocal </span>
   <span class="font11">observed </span>
   <span class="font11">tumor </span>
   <span class="font10">HCV </span>
   <span class="font10">ICI. </span>
   <span class="font10">approach </span>
   <span class="font10">even </span>
   <span class="font10">infections </span>
   <span class="font10">management </span>
   <span class="font10">safety </span>
   <span class="font10">virus </span>
   <span class="font10">CTLA- </span>
   <span class="font10">Clin </span>
   <span class="font10">Dis;:â€". </span>
   <span class="font10">ICI-treated </span>
   <span class="font10">Infect </span>
   <span class="font10">caused </span>
   <span class="font10">evidence </span>
   <span class="font10">including </span>
   <span class="font10">infectious </span>
   <span class="font10">nivolumab </span>
   <span class="font10">other </span>
   <span class="font10">patient </span>
   <span class="font10">patients. </span>
   <span class="font10">phase </span>
   <span class="font10">received </span>
   <span class="font10">respiratory </span>
   <span class="font10">there </span>
   <span class="font10">treatment. </span>
   <span class="font10">which </span>
   <span class="font10">Cancer </span>
   <span class="font10">Hence, </span>
   <span class="font10">ICI-induced </span>
   <span class="font10">antiviral </span>
   <span class="font10">blockade </span>
   <span class="font10">coronavirus </span>
   <span class="font10">cytokine </span>
   <span class="font10">during </span>
   <span class="font10">higher </span>
   <span class="font10">infections, </span>
   <span class="font10">one </span>
   <span class="font10">px; </span>
   <span class="font10">response </span>
   <span class="font10">study </span>
   <span class="font10">than </span>
   <span class="font10">without </span>
   <span class="font10">{font-family </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">Similar </span>
   <span class="font10">available </span>
   <span class="font10">but </span>
   <span class="font10">cytokines </span>
   <span class="font10">death </span>
   <span class="font10">effective </span>
   <span class="font10">expressed </span>
   <span class="font10">font-size </span>
   <span class="font10">frequently </span>
   <span class="font10">however, </span>
   <span class="font10">inhibition </span>
   <span class="font10">inhibitory </span>
   <span class="font10">irAE </span>
   <span class="font10">progressive </span>
   <span class="font10">recently </span>
   <span class="font10">receptor </span>
   <span class="font10">responses </span>
   <span class="font10">review </span>
   <span class="font10">studies </span>
   <span class="font10">therapeutic </span>
   <span class="font10">these </span>
   <span class="font10">treated </span>
   <span class="font10">versus </span>
   <span class="font10">when </span>
   <span class="font10">whether </span>
   <span class="font10">(eg, </span>
   <span class="font10">IL- </span>
   <span class="font10">Immunother </span>
   <span class="font10">Indeed, </span>
   <span class="font10">PLoS </span>
   <span class="font10">PML </span>
   <span class="font10">against </span>
   <span class="font10">and/or </span>
   <span class="font10">autoimmune </span>
   <span class="font10">cancer. </span>
   <span class="font10">cause </span>
   <span class="font10">cells. </span>
   <span class="font10">considered </span>
   <span class="font10">currently </span>
   <span class="font10">double; </span>
   <span class="font10">events </span>
   <span class="font10">example, </span>
   <span class="font10">increase </span>
   <span class="font10">infected </span>
   <span class="font10">inhibitors: </span>
   <span class="font10">lymphocyte </span>
   <span class="font10">lymphocytes, </span>
   <span class="font10">many </span>
   <span class="font10">more </span>
   <span class="font10">occurrence </span>
   <span class="font10">only </span>
   <span class="font10">particular </span>
   <span class="font10">particularly </span>
   <span class="font10">predominantly </span>
   <span class="font10">reactivation </span>
   <span class="font10">solid </span>
   <span class="font10">will </span>
   <span class="font10">./s--- </span>
   <span class="font10">Based </span>
   <span class="font10">COVID-, </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">ICIs </span>
   <span class="font10">Importantly, </span>
   <span class="font10">Med;:â€". </span>
   <span class="font10">Moreover, </span>
   <span class="font10">Notably, </span>
   <span class="font10">Oncol;:â€". </span>
   <span class="font10">PML. </span>
   <span class="font10">SARS-COV- </span>
   <span class="font10">Since </span>
   <span class="font10">This </span>
   <span class="font10">agents </span>
   <span class="font10">al.Safety </span>
   <span class="font10">all </span>
   <span class="font10">among </span>
   <span class="font10">appears </span>
   <span class="font10">authors </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">care </span>
   <span class="font10">concurrent </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">course </span>
   <span class="font10">developed </span>
   <span class="font10">did </span>
   <span class="font10">different </span>
   <span class="font10">discussed </span>
   <span class="font10">effects </span>
   <span class="font10">following </span>
   <span class="font10">high </span>
   <span class="font10">highly </span>
   <span class="font10">important </span>
   <span class="font10">inhibitors. </span>
   <span class="font10">investigating </span>
   <span class="font10">leukoencephalopathy. </span>
   <span class="font10">lymphoid </span>
   <span class="font10">might </span>
   <span class="font10">mortality </span>
   <span class="font10">number </span>
   <span class="font10">possible </span>
   <span class="font10">programmed </span>
   <span class="font10">proteins </span>
   <span class="font10">research </span>
   <span class="font10">results </span>
   <span class="font10">severity </span>
   <span class="font10">similar </span>
   <span class="font10">solid; </span>
   <span class="font10">systematic </span>
   <span class="font10">therapy. </span>
   <span class="font10">trial </span>
   <span class="font10">trials </span>
   <span class="font10">vaccine </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">â€" </span>
   <span class="font10">(ie, </span>
   <span class="font10">(n=). </span>
   <span class="font10">./S-()- </span>
   <span class="font10">./imt-- </span>
   <span class="font10">./journal.ppat. </span>
   <span class="font10">Cancer;:. </span>
   <span class="font10">Guillain-BarrÃ© </span>
   <span class="font10">HIV- </span>
   <span class="font10">IL-, </span>
   <span class="font10">Immunol;:â€". </span>
   <span class="font10">Oncol </span>
   <span class="font10">Pathog;:e. </span>
   <span class="font10">Rev </span>
   <span class="font10">SARS-COV </span>
   <span class="font10">about </span>
   <span class="font10">acute </span>
   <span class="font10">al.Clinical </span>
   <span class="font10">al.Influenza </span>
   <span class="font10">animal </span>
   <span class="font10">antibody </span>
   <span class="font10">antitumor </span>
   <span class="font10">approved </span>
   <span class="font10">between </span>
   <span class="font10">binding </span>
   <span class="font10">bold </span>
   <span class="font10">can </span>
   <span class="font10">cancer: </span>
   <span class="font10">cases </span>
   <span class="font10">cases. </span>
   <span class="font10">cells, </span>
   <span class="font10">complete </span>
   <span class="font10">could </span>
   <span class="font10">courier; </span>
   <span class="font10">demonstrated </span>
   <span class="font10">diseases </span>
   <span class="font10">em; </span>
   <span class="font10">employed </span>
   <span class="font10">enhance </span>
   <span class="font10">events. </span>
   <span class="font10">experience </span>
   <span class="font10">factors </span>
   <span class="font10">fatal </span>
   <span class="font10">further </span>
   <span class="font10">immune-mediated </span>
   <span class="font10">immune-related </span>
   <span class="font10">incidence </span>
   <span class="font10">infection, </span>
   <span class="font10">infections. </span>
   <span class="font10">initial </span>
   <span class="font10">leading </span>
   <span class="font10">leukoencephalopathy </span>
   <span class="font10">melanoma </span>
   <span class="font10">most </span>
   <span class="font10">new </span>
   <span class="font10">non-small </span>
   <span class="font10">novel </span>
   <span class="font10">per </span>
   <span class="font10">peripheral </span>
   <span class="font10">pneumonitis </span>
   <span class="font10">proinflammatory </span>
   <span class="font10">pt;} </span>
   <span class="font10">review. </span>
   <span class="font10">significantly </span>
   <span class="font10">some </span>
   <span class="font10">stage </span>
   <span class="font10">standard </span>
   <span class="font10">still </span>
   <span class="font10">study. </span>
   <span class="font10">those </span>
   <span class="font10">through </span>
   <span class="font10">thus </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">under </span>
   <span class="font10">vaccines </span>
   <span class="font10">well </span>
  </p>
 </body>
</html>
